Autolus Therapeutics (AUTL) Competitors

$1.62 -0.13 (-7.43%)

Closing price 04:00 PM Eastern

Extended Trading

$1.68 +0.06 (+3.77%)

As of 06:08 PM Eastern

AUTL vs. NRIX, RAPP, OCUL, SRPT, and VCEL

Should you buy Autolus Therapeutics stock or one of its competitors? MarketBeat compares Autolus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Autolus Therapeutics include Nurix Therapeutics (NRIX), Rapport Therapeutics (RAPP), Ocular Therapeutix (OCUL), Sarepta Therapeutics (SRPT), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry.

How does Autolus Therapeutics compare to Nurix Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Autolus Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.86, indicating that its stock price is 86% more volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Autolus Therapeutics has a net margin of -311.98% compared to Nurix Therapeutics' net margin of -411.37%. Nurix Therapeutics' return on equity of -64.21% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

Autolus Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 440.12%. Nurix Therapeutics has a consensus target price of $30.46, suggesting a potential upside of 96.78%. Given Autolus Therapeutics' higher possible upside, equities research analysts clearly believe Autolus Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Nurix Therapeutics has higher revenue and earnings than Autolus Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.72	-$287.53M	-$1.09	N/A
Nurix Therapeutics	$83.98M	19.06	-$264.46M	-$3.16	N/A

In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 1 articles in the media. Nurix Therapeutics' average media sentiment score of 1.89 beat Autolus Therapeutics' score of 0.96 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Autolus Therapeutics	Positive
Nurix Therapeutics	Very Positive

Summary

Autolus Therapeutics beats Nurix Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to Rapport Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

72.8% of Autolus Therapeutics shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Rapport Therapeutics had 4 more articles in the media than Autolus Therapeutics. MarketBeat recorded 5 mentions for Rapport Therapeutics and 1 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.96 beat Rapport Therapeutics' score of 0.58 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Autolus Therapeutics	Positive
Rapport Therapeutics	Positive

Rapport Therapeutics has lower revenue, but higher earnings than Autolus Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.72	-$287.53M	-$1.09	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Autolus Therapeutics presently has a consensus target price of $8.75, indicating a potential upside of 440.12%. Rapport Therapeutics has a consensus target price of $58.83, indicating a potential upside of 59.01%. Given Autolus Therapeutics' higher possible upside, research analysts plainly believe Autolus Therapeutics is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Autolus Therapeutics has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Rapport Therapeutics has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Rapport Therapeutics' return on equity of -24.78% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Summary

Autolus Therapeutics beats Rapport Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to Ocular Therapeutix?

Autolus Therapeutics (NASDAQ:AUTL) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Autolus Therapeutics has a net margin of -311.98% compared to Ocular Therapeutix's net margin of -558.24%. Ocular Therapeutix's return on equity of -64.28% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

In the previous week, Ocular Therapeutix had 7 more articles in the media than Autolus Therapeutics. MarketBeat recorded 8 mentions for Ocular Therapeutix and 1 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.96 beat Ocular Therapeutix's score of -0.17 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Autolus Therapeutics	Positive
Ocular Therapeutix	Neutral

Ocular Therapeutix has lower revenue, but higher earnings than Autolus Therapeutics. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.72	-$287.53M	-$1.09	N/A
Ocular Therapeutix	$51.95M	35.19	-$265.94M	-$1.46	N/A

Autolus Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 440.12%. Ocular Therapeutix has a consensus price target of $23.78, suggesting a potential upside of 184.76%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Autolus Therapeutics is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Autolus Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

Summary

Autolus Therapeutics beats Ocular Therapeutix on 12 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Sarepta Therapeutics presently has a consensus price target of $27.17, indicating a potential upside of 67.33%. Autolus Therapeutics has a consensus price target of $8.75, indicating a potential upside of 440.12%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Sarepta Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

Sarepta Therapeutics has a net margin of -2.94% compared to Autolus Therapeutics' net margin of -311.98%. Sarepta Therapeutics' return on equity of 7.56% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

In the previous week, Sarepta Therapeutics had 2 more articles in the media than Autolus Therapeutics. MarketBeat recorded 3 mentions for Sarepta Therapeutics and 1 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.96 beat Sarepta Therapeutics' score of 0.82 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sarepta Therapeutics	Positive
Autolus Therapeutics	Positive

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Autolus Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.18B	0.78	-$713.41M	-$0.96	N/A
Autolus Therapeutics	$75.39M	5.72	-$287.53M	-$1.09	N/A

Summary

Autolus Therapeutics beats Sarepta Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Vericel?

Autolus Therapeutics (NASDAQ:AUTL) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Autolus Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, Vericel has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Vericel has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.72	-$287.53M	-$1.09	N/A
Vericel	$292.09M	6.07	$16.52M	$0.42	82.71

72.8% of Autolus Therapeutics shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 7.6% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vericel has a net margin of 7.35% compared to Autolus Therapeutics' net margin of -311.98%. Vericel's return on equity of 6.41% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Vericel	7.35%	6.41%	4.61%

In the previous week, Vericel had 1 more articles in the media than Autolus Therapeutics. MarketBeat recorded 2 mentions for Vericel and 1 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.96 beat Vericel's score of 0.93 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Autolus Therapeutics	Positive
Vericel	Positive

Autolus Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 440.12%. Vericel has a consensus price target of $55.40, suggesting a potential upside of 59.47%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Vericel beats Autolus Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Autolus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUTL vs. The Competition

Export

Metric	Autolus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$431.15M	$3.28B	$6.25B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-1.49	17.93	22.29	24.19
Price / Sales	5.72	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	2.42	6.63	9.84	6.72
Net Income	-$287.53M	$24.20M	$3.57B	$337.19M
7 Day Performance	-3.57%	-3.24%	-1.17%	0.48%
1 Month Performance	10.20%	0.53%	3.84%	5.06%
1 Year Performance	-21.74%	47.24%	27.39%	34.27%

Autolus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUTL Autolus Therapeutics	3.4007 of 5 stars	$1.62 -7.4%	$8.75 +440.1%	-8.4%	$431.15M	$75.39M	N/A	330
NRIX Nurix Therapeutics	2.8828 of 5 stars	$17.50 flat	$30.46 +74.1%	+34.8%	$1.81B	$83.98M	N/A	300
RAPP Rapport Therapeutics	3.297 of 5 stars	$37.72 flat	$58.83 +56.0%	+271.3%	$1.80B	N/A	N/A	N/A	Analyst Forecast
OCUL Ocular Therapeutix	2.6964 of 5 stars	$8.23 flat	$23.78 +188.9%	+2.5%	$1.80B	$51.95M	N/A	230
SRPT Sarepta Therapeutics	3.2844 of 5 stars	$16.80 flat	$27.17 +61.7%	-56.9%	$1.77B	$2.20B	N/A	1,372

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUTL) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Autolus Therapeutics (AUTL) Competitors

AUTL vs. NRIX, RAPP, OCUL, SRPT, and VCEL

How does Autolus Therapeutics compare to Nurix Therapeutics?

Summary

How does Autolus Therapeutics compare to Rapport Therapeutics?

Summary

How does Autolus Therapeutics compare to Ocular Therapeutix?

Summary

How does Autolus Therapeutics compare to Sarepta Therapeutics?

Summary

How does Autolus Therapeutics compare to Vericel?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Autolus Therapeutics (AUTL) Competitors

AUTL vs. NRIX, RAPP, OCUL, SRPT, and VCEL

How does Autolus Therapeutics compare to Nurix Therapeutics?

Which has more risk & volatility, AUTL or NRIX?

Do institutionals and insiders believe in AUTL or NRIX?

Is AUTL or NRIX more profitable?

Do analysts rate AUTL or NRIX?

Which has stronger valuation & earnings, AUTL or NRIX?

Does the media prefer AUTL or NRIX?

Summary

How does Autolus Therapeutics compare to Rapport Therapeutics?

Do insiders and institutionals have more ownership in AUTL or RAPP?

Does the media prefer AUTL or RAPP?

Which has better valuation and earnings, AUTL or RAPP?

Do analysts rate AUTL or RAPP?

Which has more volatility & risk, AUTL or RAPP?

Is AUTL or RAPP more profitable?

Summary

How does Autolus Therapeutics compare to Ocular Therapeutix?

Is AUTL or OCUL more profitable?

Does the media refer more to AUTL or OCUL?

Which has higher earnings & valuation, AUTL or OCUL?

Do analysts rate AUTL or OCUL?

Do insiders and institutionals hold more shares of AUTL or OCUL?

Which has more volatility & risk, AUTL or OCUL?

Summary

How does Autolus Therapeutics compare to Sarepta Therapeutics?

Do analysts prefer SRPT or AUTL?

Which has more volatility & risk, SRPT or AUTL?

Is SRPT or AUTL more profitable?

Does the media prefer SRPT or AUTL?

Do insiders & institutionals have more ownership in SRPT or AUTL?

Which has stronger earnings and valuation, SRPT or AUTL?

Summary

How does Autolus Therapeutics compare to Vericel?

Which has more risk & volatility, AUTL or VCEL?

Which has stronger earnings and valuation, AUTL or VCEL?

Do institutionals and insiders hold more shares of AUTL or VCEL?

Is AUTL or VCEL more profitable?

Does the media prefer AUTL or VCEL?

Do analysts rate AUTL or VCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools